Your search for ESKD returned 43 results

Psoriasis may be another risk factor for infectious complications in patients receiving dialysis, according to investigators.

In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.

Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.

End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.

Canagliflozin decreases the risk of kidney failure in patients with chronic kidney disease and type 2 diabetes, according to a new study.

Patients with end-stage kidney disease (ESKD) undergoing maintenance dialysis express a desire to exercise to regain energy and strength, but many report barriers to exercise.

The researchers found that an estimated 1% absolute increase in quarterly ILI correlated with a 1.5% increase and a 2.0% increase in relative mortality for quarters 4 and 1, respectively.

“We believe that the data actually suggest possible benefit for ESKD [end-stage kidney disease] with intensive glucose control, and remain inconclusive for intensive blood pressure control and fibrate use given the wide confidence intervals for the more reliable ESKD outcomes,” write the authors.

“CKD staged by level of eGFR and proteinuria characterizes the timeline of progression and can guide management strategies in children,” the authors write.

Shorter sleep duration, greater sleep fragmentation linked to greater decline in eGFR